Chronic GVHD Treatment Overview: Immunosuppressives, New Agents, and What Patients Need to Know

Opinion
Video

Panelists discuss how the current treatment landscape for chronic graft-versus-host disease includes a range of immunosuppressive approaches, from traditional corticosteroids and calcineurin inhibitors to newer approved agents like axatilimab, ruxolitinib, belumosudil, ibrutinib, and abatacept, emphasizing key considerations patients should be aware of when undergoing these therapies.

Video content above is prompted by the following:

Let's discuss the current treatment landscape for cGVHD, including emerging therapies and their potential impact on patient care.

  • Can you provide an overview of the current treatment approaches for cGVHD? Please highlight GVHD management relies on immunosuppressive treatments like corticosteroids, calcineurin inhibitors, and monoclonal antibodies. Several agents have been approved for various GVHD settings, including axatilimab, ruxolitinib, belumosudil, ibrutinib, and abatacept.
    • What key things should patients be aware of when receiving therapies?

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
4 experts in this video
4 experts in this video
Image of a woman with light brown hair wearing glasses with a blue background
Image of a woman wearing glasses in front of a blue background
Image of a woman with glasses in front of a blue background
Image of a man in a suit smiling in front of an Oncology Nursing News background
Image of a woman wearing a patterned shirt in front of a dark blue background
Photo of a woman wearing a blazer in front of an Oncology Nursing News backdrop
3 experts in this video
3 experts in this video
Related Content
Image of red blood cells

FDA Declines Breakthrough Status, Halts Itolizumab’s Path Forward in Acute GVHD

Roman Fabbricatore
April 27th 2025
Article

The FDA’s decision not to grant breakthrough designation or accelerated approval for itolizumab in acute GVHD has led to the discontinuation of the pivotal phase 3 EQUATOR trial.

Photo of a patient holding a prescription bottle of pills and speaking with a doctor holding a clipboard

Pacritinib Shows Preliminary ORR in Chronic Graft-Vs-Host Disease

Kristi Rosa
April 9th 2025
Article

Pacritinib showed early activity and was safe for patients with multi-refractory chronic graft-vs-host disease.

dark blue background with a white outline indicating blood cells

MaaT013 Achieves Primary Endpoint in ARES Trial for GI-aGVHD

Kyle Doherty
January 16th 2025
Article

MaaT013 showed positive results in the phase 3 ARES trial, meeting its primary endpoint of GI-ORR at day 28 in patients with third-line GI-aGVHD.

diverse hands being raised

How to Overcome 4 Common Barriers to Cancer Clinical Trial Access

Brielle Benyon
November 7th 2024
Article

An oncology nurse discusses 4 common barriers certain patient populations face when it comes to oncology clinical trials, and what clinicians can do to mitigate these disparities.

FDA Approves Axatilimab for Chronic Graft-vs-Host Disease

FDA Approves Axatilimab for Chronic Graft-vs-Host Disease

Darlene Dobkowski, MA
August 14th 2024
Article

The FDA approved axatilimab for adults and children with chronic graft-vs-host disease whose disease progressed after 2 or more lines of systemic therapy.

BLA Resubmission Accepted by the FDA for Remestemcel-L in Pediatric Steroid-Refractory aGVHD

BLA Resubmission Accepted by the FDA for Remestemcel-L in Pediatric Steroid-Refractory aGVHD

Chris Ryan
August 11th 2024
Article

The biologics license application that was resubmitted for remestemcel-L has been accepted by the FDA for the potential treatment of children with steroid-refractory acute graft-vs-host-disease.